

## Predictive. Prognostic. Personalized.

The future of genitourinary oncology is precision treatment. **Lead the way, with confidence.**

### What is Vesta?

Vesta is Valar Labs' GU-focused portfolio of AI-powered pathology tests, which can:

Predict patients' response to key anti-cancer treatments ► **Vesta® Bladder BCGPredict**

Quantify risks of recurrence and progression ► **Vesta® Bladder Risk Stratify**

### How?



#### Novel Biomarkers

Valar Labs' research team has developed and validated multiple unique Vesta biomarker models in over 1,000 patients with Non-Muscle Invasive Bladder Cancer (NMIBC) using histology features.



#### Expertly Trained AI

Valar Labs' board-certified pathologists created 500,000+ annotations of tumors and their microenvironment to train our Computational Histology Artificial Intelligence (CHAI) platform, grounding the technology in biology.



#### Fast, H&E-Based Testing

Leveraging existing tumor specimens, first-of-its-kind AI analyzes pathology slides and returns actionable results in days for timely treatment decisions.

### The Results ► Informed, efficient care for patients with NMIBC.

#### Vesta® Bladder BCGPredict

Predict your patient's response to BCG.

The standard of care for NMIBC is **not effective** in up to 40% of patients.

Understand what's best for each individual by adding personalized data to your clinical management strategy.

- By unlocking key features of the tumor and its microenvironment, our AI-powered test identifies patients at a higher risk of not responding to BCG.<sup>1,2</sup>
- Patients who test biomarker-present demonstrated a higher likelihood of success with an alternative therapy.<sup>3</sup>


#### Vesta Bladder BCGPredict

##### BIOMARKER PRESENT

This patient has the Vesta® Bladder BCGPredict Biomarker and is likely to have worse outcomes with BCG therapy compared to patients without this biomarker. Alternative treatment modalities may be considered based on this result [1-4]. (raw score: -0.09)

##### Supplemental Clinical Evidence


Clinical Outcomes on BCG vs Alternative Therapy, by Vesta® Bladder BCGPredict Biomarker Status



In a recent publication, patients with the Vesta® Bladder BCGPredict Biomarker present demonstrated significantly higher recurrence rates when treated with BCG compared to treatment with intravesical sequential gemcitabine/docetaxel.

Patients for whom the Vesta® Bladder BCGPredict Biomarker was absent demonstrated no significant difference in recurrence rates when treated with BCG or intravesical sequential gemcitabine/docetaxel [1].

Adapted from Packham et al. European Urology Oncology 2025



 Valar Labs

Every decision is critical.  
Make every decision informed.

